Avacta Group has released detailed pre-clinical, clinical, and pharmacokinetic data from the Phase 1a dose escalation study of its lead pre|CISIONTM programme, AVA6000. The data confirms the platform's ability to target the release of chemotherapy specifically to the tumor microenvironment, reducing systemic exposure and improving the safety profile of the drug. AVA6000 has shown significant improvements in the safety and tolerability of doxorubicin, with a reduction in the frequency and severity of known toxicities. Preliminary clinical results also demonstrate anti-tumor activity in patients with high FAP activity. The next steps involve optimizing the patient population, dose, and schedule to increase efficacy and tolerability. A fortnightly dosing study is currently screening patients in the United States to assist in optimizing the schedule and dose for a potentially pivotal Phase 2 study in 2024.